This Week in the Journal

The annual decline in the prebronchodilator FEV1 was similar in the two groups, but a benefit from tiotropium was seen in postbronchodilator FEV1 . see (Original Article, N Engl J Med 2017;377:923-935) Tezepelumab in Adults with Uncontrolled Asthma Treatment with tezepelumab, a human monoclonal antibody specific for thymic stromal lymphopoietin, reduced exacerbation frequency among patients whose asthma remained uncontrolled with long-acting beta-agonists and medium-to-high doses of inhaled glucocorticoids. see (Original Article, N Engl J Med 2017;377:936-946) Third Dose of MMR Vaccine Outbreaks of mumps virus infection are occurring with increased frequency, especially on college campuses.In this report, the use of a third dose of the MMR vaccine was shown to significantly contribute to outbreak control. see (Original Article, N Engl J Med 2017;377:947-956) Trials in Health Insurance Systems This review article considers the strengths and weaknesses of randomized clinical trials that are conducted through the analysis of data gathered by health insurers. see (Review Article, N Engl J Med 2017;377:957-964) Severe and Difficult-to-Treat Asthma in Adults Adults with severe asthma consume substantial human and financial resources.In the preceding 3 months, back pain, hip flexor weakness, and numbness of a finger had developed, followed by weakness and shooting pains in her limbs and weakness in facial muscles. see (Clinical Problem-Solving, N Engl J Med 2017;377:978-984) From Last to First Commonwealth Fund reports have consistently rated the performance of the U.S. health care system last among high-income countries, though we spend far more on health care..

Medienart:

Artikel

Erscheinungsjahr:

2017

Erschienen:

2017

Enthalten in:

Zur Gesamtaufnahme - volume:377

Enthalten in:

The New England journal of medicine - 377(2017), 10, Seite 910

Sprache:

Englisch

Links:

search.proquest.com

BKL:

44.60

44.00

Themen:

Asthma
Bronchitis
Clinical medicine
Drug dosages
Health care policy
Health risk assessment
Pain
Pneumonia
Vaccines

RVK:

RVK Klassifikation

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

OLC1998016080